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Characterization of antiepileptic drug therapy for achieving seizure 
cessation in patients with benzodiazepine-resistant status epilepticus 
 
 Introduction 
 According to the 2012 Neurocritical Care Society guidelines, status epilepticus (SE) is 
defined as greater than 5 minutes of continuous seizure activity or greater than or equal to 2 
discrete seizures without full recovery of consciousness. Refractory SE (RSE) or 
benzodiazepine-resistant SE is defined as SE that does not respond to adequate doses of initial 
benzodiazepines and requires treatment with a second acceptable antiepileptic drug (AED). 1    
 SE is one of the most commonly encountered neurological emergencies with 
approximately 150,000 cases in the United States, accounting for 40,000 deaths per year.2 The 
overall mortality associated with SE approaches 20%, with generalized convulsive SE 
representing about 45-75% of all cases and estimated direct inpatient cost of $4 billion in the 
USA.8  
 SE shows a time-dependent increase in mortality and resistance to treatment. 3 The 
primary concern is that epilepsy will develop in about 20 to 40% of patients after a single 
episode of SE.9 Pathologically, however, hippocampal neurons begin to die after 30 minutes of 
sustained seizure activity and those patients who do survive RSE are more likely to experience 
further epileptic episodes than those with benzodiazepine-responsive SE (88% vs 22%). 1,9 
Therefore, timely treatment of these episodes is indicated to prevent potentially deleterious 
complications such as chronic encephalopathy and consequently, severe disability. 1,4,9  
 As a first line, benzodiazepines fail to provide seizure cessation for 35-45% of patients 
with SE and additional treatments are needed, for which convincing evidence is lacking.4  
Neurocritical Care Guideline (2012) recommendations for treatment of RSE are primarily based 
on expert opinion and less rigorous data, where use of one or more of the following agents is not 
unreasonable: valproate, levetiracetam, phenytoin, lacosamide, phenobarbital, topiramate, and/or 
pentobarbital.1  
 In 2013, a meta-analysis of 27 papers comparing effectiveness of five AEDs for the 
treatment of RSE was published, in which 77.7% of studies were observational and characterized 
by considerable heterogeneity and wide confidence intervals. This analysis concluded that 
valproate, levetiracetam, and phenobarbital could all be used as first line therapy in RSE; 
however, the evidence did not support the first-line use of phenytoin, which is the only AED 
with an FDA-approved indication for SE.  Additionally, lacosamide studies were excluded due to 
insufficient data.5, 6  
 The medication profiles of currently available AEDs for the treatment of RSE vary 
widely in their severity of side effects, drug-drug interactions, and necessity for blood level 
monitoring.  In approximately 25% of patients, side effects lead to the discontinuation of the 
selected treatment and have a substantial negative impact on patients’ quality of life.3  
 Due to a lack of evidence regarding choice of AED for RSE, there is a need to elucidate 
the comparative effectiveness and safety of these agents in patients with seizures not responding 
to benzodiazepines. The purpose of this study was to characterize the utilization of antiepileptic 
drugs for the induction of seizure cessation in patients with benzodiazepine-resistant status 
epilepticus at a community hospital in comparison to current literature. 
 Methods 
 This institutional review board approved study was a retrospective electronic chart 
review of adults presenting with a SE event during the study period of December 2006 through 
December 2014. Inclusion criteria consisted of patients aged 18 and older who were treated for at 
least one episode of benzodiazepine-resistant SE with AED therapy during the admission who 
had continuous EEG monitoring for at least 1 hour. Patients with subclinical seizures were 
included in the study. Patients were excluded for the following reasons: re-admittance for seizure 
event within the study period, hypothermia as indication for EEG monitoring and participation in 
an AED clinical trial. Seizure cessation was defined as discontinuation of continuous EEG 
(cEEG) monitoring and absence of reinitiating cEEG within 24 hours for seizure monitoring 
purposes. Coma was defined as initiation of continuous infusion of anesthetic medications and 
dose titration to burst suppression on cEEG. The primary outcome of this study was to identify 
the average number of AEDs needed to stop benzodiazepine-resistant SE. Secondary outcomes 
included the average number of AEDs used in patients with and without history of seizure; 
average loading, maintenance, and total dose of AEDs used; percentage of patients with seizure 
cessation, coma or death; and percentage of patients intubated. Data collected included patient 
age, sex, race, ethnicity, weight, height, body mass index, estimated creatinine clearance, number 
of AEDs taken prior to admission and at discharge, seizure type and history, seizure etiology, 
rate of intubation, patient outcomes (seizure cessation, coma, death), individual AED dose, 
frequency, route, rate, and documented adverse events. Data was analyzed using quantitative 
statistics. 
 Results 
 A total of 161 patients were screened for inclusion and 65 patients met the required 
criteria (figure 1). Baseline characteristics are presented in Table 1. Patients needed a median of 
3 AEDs (interquartile 1-6) to achieve seizure cessation. However, patients with medically 
induced coma required median of 4 AEDs (interquartile 2-5) for seizure cessation that reflected 
in Table 2. There were 33.8% and 78.6% of patients taking 1 or 2 AEDs prior to admission and 
at discharge, respectively, with levateracetam being the most frequently prescribed AED (figure 
2). The most frequently used first or second line AEDs were levetiracetam (35.4%) and 
phenytoin (26.2%, table 3).  Utilization of AEDs including loading, maintenance, total doses and 
dosing interval is similar to current guideline recommendations (table 4). 
 Discussion  
 In our study population patients with benzodiazepine-resistant SE required a median of 3 
AEDs for treatment with levateracetam and phenytoin being the most frequently utilized agents 
after benzodiazepine failed. These findings are consistent with other observational study results7. 
However, levateracetam was more frequently used as a second line compared to phenytoin in the 
present study (35.4 vs 26.2%, respectively), whereas 2012 study found phenytoin to be more 
frequently used AED than levateracetam (33.3 vs 10%, respectively)7. The lower number of 
patients with the history of seizure in this study compared to previous literature and the high 
frequency of levateracetam utilization in patients prior to admission may explain the difference 
in our findings.  
 This study has several limitations that are worse mentioning. First, retrospective nature of 
the study, single center involvement and small sample size resulted in low generalizability and 
inability to ascertain causative relations. Reliance on ICD-9 codes and manual chart reviewing 
presented challenges in accurate patients inclusion, missing information concerning seizure 
features, adverse events and outcomes. Second, due to not stratifying patients based on 
adherence, we could not determine weather patients had progression of their condition or 
decreased seizure control. Third, not well defined and time-sensitive nature of status epilepticus, 
additive effect of previously administered AEDs, led to difficulty in determining the true number 
of AEDs needed for seizure cessation.  
 Conclusion  
 This study adds to the body of literature by affirming similar practice pattern among 
different institutions in terms of management of status epilepticus. Primarily, the average number 
of AEDs administered that is associated with seizure cessation in the settings of benzodiazepine-
resistant status epilepticus. Conversely, the most frequently used agent in our institution was 
levateracetam. The future avenues to study may include adverse events profile, cost savings and 
length of stay for patients with benzodiazepine-resistant status epilepticus. 
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Figure 1: Patient Selection 
 
 
 
 
 
 
 
 
 
 
Screened N=161 
Included N=65 
Excluded N=96 
No EEG report N=32 
Date not in range N=26 
Hypothermia N=11 
Readmitted N=6 
Full treatment not available N=5 
EEG length not qualified N=5 
No seizure on EEG report N=5 
Seizure managed on benzodiazepines N=4 
No record of benzodiazepine use N=2 
 
a4 patients with history unknown 
Table 1: Baseline Characteristics  
 
Total participants (n) 65 
Age in years, median (range)  62 (18-89) 
Sex, n (%)  
    Female 39 (60.0) 
Race, n (%)  
    White 55 (84.6) 
    Other/Unknown 10  (15.5) 
Weight in kg, median (range) 69 (34-120) 
BMI in kg/m2, median (range) 25 (17-41) 
Patients with history of seizure (n, %)a 22 (33.8) 
Seizure etiology, n (%)  
    Primary epilepsy  11 (16.9) 
    Trauma  6   (9.2) 
    Subarachnoid hemorrhage  5   (7.7) 
    Infectious  5   (7.7) 
    Unknown 27 (41.5) 
Seizure type, n (%)  
    Generalized  37 (56.9%) 
    Focal  17 (26.2%) 
    Unknown  11 (16.9%) 
Outcomes Patients, n (%) # of AEDs used during 
admission, median 
(range) 
Expired 9 (13.8) 3 (3-4) 
Discharged 56 (86.2) 3 (1-6) 
Intubated 43 (66.2) 3 (1-6) 
Coma 9 (13.8) 4 (2-5) 
With history of seizure 22 (33.8) 3 (1-5) 
Without history of seizure 39 (60.0) 3 (1-6) 
 
Table 2: Secondary Outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: AED Therapy Prescribed 
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Figure 3: Last AED Used for Seizure Cessation 
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Drug,  
n (%) 
1st 
line 
2nd 
line 
3rd 
line 
4th 
line 
5th 
line 
6th 
line 
Last AEDa 
 n=65 n=61 n=40 n=18 n=5 n=1 n=65 
Lacosamide 5 
(7.7) 
6  
(9.8) 
8 
(20.0) 
3 
(16.7) 
- - 11 (16.9) 
Levetiracetam 23 
(35.4) 
12 
(19.7) 
5 
(12.5) 
1  
(5.6) 
- - 10 (15.4) 
Phenytoinb 17 
(26.2) 
16 
(26.2) 
10 
(25.0) 
- 1 
(20.0) 
- 16 (24.6) 
Valproic Acid 6 
(9.2) 
9 (14.8) 4 
(10.0) 
3 
(16.7) 
1 
(20.0) 
- 6 (9.2) 
Fosphenytoin 3 
(4.6) 
5 (8.2) 2 (5.0) - - - - 
Other 11 
(16.9) 
13 
(21.3) 
11 
(27.5) 
11 
(61.1) 
3 
(60.0) 
1 
(100) 
22 (33.8) 
 
a last is last AED given in the treatment, could be 1st – 6th AED used depending on patient 
b one patient received phenytoin as first and third AEDs 
 
Table 3: Frequency of AEDs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Phenytoin 
(n=43)a 
Levetiracetam 
(n=41) 
Valproic Acid 
(n=23)b 
Lacosamide 
(n=22) 
Fosphenytoin 
(n=10)c 
Loading dose 
administered  
(n, %) 
33 (76.7) 28 (68.3) 21 (91.3) 12 (54.5) 9 (90) 
Loading dose 
in mg, 
median 
(range) 
1000 
(180-2000) 
1000  
(500-1500) 
1000  
(250-2300) 
150  
(50-200) 
900  
(450-1458) 
mg/PE 
Interval 
frequency in 
hr, median  
8  12  8  12 8 
Maintenance 
dose in mg, 
median 
(range) 
100  
(100-500) 
1000  
(100-2000) 
500  
(250-750) 
100  
(50-200) 
613  
(125-1100) 
mg/PE 
Total dose 
administered 
in mg, 
median 
(range) 
1600  
(200-4700) 
6500  
(500-16500) 
5220  
(1250-13300) 
875  
(200-2650) 
1175  
(450-4225) 
mg/PE 
 
a one patient received phenytoin as first and third AEDs; two patients had loading dose but no 
maintenance dose noted 
b one patient had no frequency recorded 
c only 2 patients had maintenance doses given; only 1 patient had a frequency reported 
 
Table 4: AED Utilization 
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